Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival

Kawada, Kenro; Kawano, Tatsuyuki; Nagai, Kagami; Nishikage, Tetsuro; Nakajima, Yasuaki; Tokairin, Yutaka; Ogiya, Kazuo; Iwai, Takehisa

doi:10.1016/j.gie.2006.05.032

Cited by 14 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As with the most common cutaneous malignant melanoma, the role of chemotherapy, immunotherapy with interferon-alpha and radiotherapy is controversial; they have been traditionally used in the palliative setting or after a surgical relapse, with limited effi cacy. However, there are several case reports published of adjuvant radiotherapy or chemotherapy with different combinations of chemotherapy, such as dacarbazine or carboplatin in our case, which seem to improve the overall results of surgery [17][18][19][20]. In conclusion, diagnosis at an earlier stage and radical surgery with wide margins, alongside adjuvant chemotherapy or radiotherapy in some cases, are the main measures that can improve the poor prognosis of this rare malignancy.…”

Section: Discussionmentioning

confidence: 71%

Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy

et al. 2010

View full text Add to dashboard Cite

We present the case of a 46-year-old woman diagnosed with a primary oesophageal melanoma (PEM), who was treated with radical surgery followed by combined chemoimmunotherapy (interferon, carboplatin, dacarbazine and external radiotherapy) and who achieved a complete response after this treatment. PEMs are rare malignancies, with less than 300 cases described in the literature. The main differential diagnosis is with metastases of skin or ocular malignant melanomas. They are usually diagnosed at advanced stages and prognosis is typically poor. The main treatment modality should be radical surgery. The role of adjuvant treatment is uncertain, although some long responses have been seen with the use of chemotherapy or immunotherapy alongside surgery.

show abstract

Section: Discussionmentioning

confidence: 71%

Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…2 Although the combination of these drugs with immunotherapies has been used based on the effectiveness against the cutaneous melanoma, 19 some case reports indicated that the drug combination contributed to PMME treatment. 20,21 Although the patient in our case received DAV for 10 months after the curative resection, it is unclear whether the adjuvant DAV prolonged patient survival. This is because DAV showed no significant effect on the metastatic PMME after it recurred.…”

Section: Discussionmentioning

confidence: 87%

A Resected Case of Primary Malignant Melanoma of the Esophagus—Early Detection of Recurrence by FDG-PET/CT

Nozaki¹,

Hato²,

Takahata³

et al. 2018

International Surgery

View full text Add to dashboard Cite

Primary malignant melanoma of the esophagus (PMME) is a rare, aggressive, therapyresistant malignant tumor arising from esophageal mucosal melanocytes. It has been reported that fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) has a clinical impact on PMME diagnosis; however, it remains unclear whether postoperative surveillance using FDG-PET/CT is useful for PMME patients. In this case study, FDG-PET/CT detected the recurrent tumors in their early stage after a curative resection of PMME. We report on a case of a 67-year-old Japanese male admitted to our hospital for the evaluation of polypoid tumors of the esophagogastric junction, which were diagnosed as PMME. He was treated with a curative resection by esophagectomy and 6 cycles of adjuvant chemotherapy of DAV (dacarbazine, nimustine, and vincristine). However, the PMME recurred 26 months after the surgery when surveillance FDG-PET/CT detected the recurrent tumors in their early stage. FDG-PET/ CT may be useful to detect recurrence in the postoperative surveillance phase for PMME patients.

show abstract

“…Other options for non-surgical or adjuvant treatment include chemotherapy, chemoradiotherapy, endocrinotherapy and immunotherapy. However, most of these treatment modalities are not widely accepted [15]. …”

Section: Discussionmentioning

confidence: 99%

Primary Malignant Melanoma of the Esophagus

Yönal

İbrişim

Songür

et al. 2013

Case Rep Gastroenterol

View full text Add to dashboard Cite

Primary malignant melanoma of the esophagus (PMME) comprises only 0.1-0.2% of all malignant esophageal tumors. PMME tumors are highly aggressive and metastasize early via hematogenic and lymphatic pathways. Treatment outcome is poor because the cancer has often advanced at the time of diagnosis. Inoperability, unsuccessful treatment with radiotherapy and chemotherapy in advanced tumors and metastases have contributed to its poor prognosis. Here, we present the endoscopic features, endoscopic ultrasonography findings and management of a PMME case.

show abstract

Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival

Cited by 14 publications

References 12 publications

Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy

Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy

A Resected Case of Primary Malignant Melanoma of the Esophagus—Early Detection of Recurrence by FDG-PET/CT

Primary Malignant Melanoma of the Esophagus

Contact Info

Product

Resources

About